See more : UPAY, Inc. (UPYY) Income Statement Analysis – Financial Results
Complete financial analysis of Cerus Corporation (CERS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cerus Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Ishikawa Seisakusho, Ltd. (6208.T) Income Statement Analysis – Financial Results
- MEC Company Ltd. (4971.T) Income Statement Analysis – Financial Results
- Heliad AG (A7A.DE) Income Statement Analysis – Financial Results
- NevGold Corp. (NAUFF) Income Statement Analysis – Financial Results
- NuScale Power Corporation (SMR) Income Statement Analysis – Financial Results
Cerus Corporation (CERS)
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 156.37M | 162.05M | 130.86M | 91.92M | 74.65M | 60.91M | 43.57M | 37.18M | 34.22M | 36.50M | 39.66M | 36.70M | 33.04M | 23.11M | 17.98M | 16.51M | 11.04M | 35.58M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 1.85M | 2.40M | 2.90M | 6.90M |
| Cost of Revenue | 69.97M | 74.95M | 63.48M | 41.16M | 33.42M | 31.63M | 22.53M | 20.30M | 23.46M | 21.18M | 22.60M | 20.62M | 18.54M | 12.05M | 12.58M | 9.67M | 5.23M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -634.00K | -600.00K | -700.00K | -700.00K |
| Gross Profit | 86.40M | 87.09M | 67.38M | 50.76M | 41.23M | 29.27M | 21.04M | 16.89M | 10.76M | 15.33M | 17.06M | 16.08M | 14.51M | 11.06M | 5.40M | 6.84M | 5.82M | 34.04M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 2.49M | 3.00M | 3.60M | 7.60M |
| Gross Profit Ratio | 55.25% | 53.75% | 51.49% | 55.23% | 55.23% | 48.06% | 48.29% | 45.42% | 31.44% | 41.99% | 43.01% | 43.82% | 43.91% | 47.87% | 30.04% | 41.43% | 52.66% | 95.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 134.25% | 125.00% | 124.14% | 110.14% |
| Research & Development | 67.64M | 64.11M | 63.69M | 64.41M | 60.38M | 42.56M | 33.71M | 31.32M | 25.64M | 21.69M | 15.19M | 7.60M | 7.18M | 5.20M | 6.37M | 10.21M | 14.96M | 29.51M | 24.13M | 27.65M | 52.48M | 56.42M | 48.25M | 34.82M | 22.50M | 29.80M | 19.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.84M | 52.41M | 48.75M | 45.99M | 37.73M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.52M | 83.34M | 81.29M | 67.02M | 66.21M | 56.84M | 52.41M | 48.75M | 45.99M | 37.79M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Other Expenses | 0.00 | -26.27M | -28.66M | -22.33M | -19.13M | 1.75M | 3.86M | -1.28M | 71.00K | 130.00K | 266.00K | 31.00K | 202.00K | 67.00K | 155.00K | 0.00 | 9.45M | 0.00 | 0.00 | 2.86M | 0.00 | 0.00 | 0.00 | 634.00K | 600.00K | 700.00K | 700.00K |
| Operating Expenses | 115.34M | 121.18M | 116.32M | 109.10M | 107.46M | 84.26M | 78.57M | 78.19M | 71.83M | 59.68M | 45.35M | 33.38M | 30.43M | 26.84M | 28.39M | 37.37M | 48.98M | 43.52M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 42.62M | 27.90M | 34.30M | 23.50M |
| Cost & Expenses | 185.30M | 196.13M | 179.80M | 150.25M | 140.88M | 115.90M | 101.10M | 98.48M | 95.30M | 80.85M | 67.96M | 54.00M | 48.97M | 38.89M | 40.97M | 47.04M | 54.21M | 45.06M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 41.98M | 27.30M | 33.60M | 22.80M |
| Interest Income | 0.00 | 5.83M | 4.92M | 3.75M | 6.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.39M | 5.83M | 4.92M | 3.75M | 6.07M | 4.01M | 3.02M | 2.45M | 1.71M | 599.00K | 520.00K | 551.00K | 964.00K | 689.00K | 302.00K | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.60M | 4.56M | 4.57M | 4.46M | 2.40M | 1.45M | 1.81M | 1.82M | 202.00K | 202.00K | 202.00K | 202.00K | 922.00K | 845.00K | 915.00K | 651.00K | 774.00K | 716.00K | 652.00K | 2.15M | 3.29M | 2.50M | 1.19M | 634.00K | 600.00K | 700.00K | 700.00K |
| EBITDA | -26.54M | -34.08M | -45.99M | -51.37M | -64.61M | -51.88M | -51.87M | -58.47M | -56.14M | -36.55M | -42.04M | -14.38M | -15.10M | -15.38M | -22.92M | -28.53M | -43.17M | -4.06M | -8.69M | -23.01M | -50.54M | -56.78M | -52.69M | -39.51M | -24.29M | -30.00M | -15.20M |
| EBITDA Ratio | -16.97% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -131.58% | -163.91% | -177.66% | -120.94% | -70.85% | -46.59% | -45.40% | -64.61% | -123.18% | -181.01% | -298.28% | -24.63% | -126.29% | -136.45% | -522.96% | -668.79% | -1,161.74% | -2,133.93% | -1,012.50% | -1,075.86% | -237.68% |
| Operating Income | -30.05M | -34.08M | -48.94M | -58.33M | -66.23M | -54.99M | -57.53M | -61.45M | -61.08M | -44.35M | -28.30M | -17.30M | -15.92M | -15.96M | -23.83M | -30.53M | -43.17M | -9.48M | -9.34M | -26.83M | -53.84M | -59.28M | -53.88M | -40.13M | -24.90M | -30.70M | -15.90M |
| Operating Income Ratio | -19.22% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -132.05% | -165.26% | -178.46% | -121.49% | -71.36% | -47.15% | -48.19% | -69.06% | -132.54% | -184.95% | -390.85% | -26.64% | -38.33% | -192.84% | -557.01% | -698.20% | -1,188.05% | -2,168.18% | -1,037.50% | -1,058.62% | -230.43% |
| Total Other Income/Expenses | -7.27M | -8.26M | -5.12M | -1.24M | -4.76M | -2.35M | 832.00K | -1.28M | 1.54M | 5.94M | -14.82M | 1.63M | -1.06M | -953.00K | -302.00K | 1.35M | 4.07M | 4.70M | 22.41M | -4.33M | -4.43M | 2.09M | 4.61M | 4.10M | 0.00 | 1.20M | 1.20M |
| Income Before Tax | -37.32M | -42.34M | -54.06M | -59.57M | -70.98M | -57.34M | -56.70M | -62.73M | -59.54M | -38.37M | -43.12M | -15.68M | -16.98M | -16.91M | -24.67M | 0.00 | -52.62M | -4.78M | 12.75M | -31.15M | -4.43M | -57.19M | -49.27M | -36.03B | 0.00 | -29.50M | -14.70M |
| Income Before Tax Ratio | -23.87% | -26.13% | -41.31% | -64.81% | -95.09% | -94.13% | -130.14% | -168.71% | -173.97% | -105.12% | -108.73% | -42.72% | -51.39% | -73.18% | -137.21% | 0.00% | -476.42% | -13.43% | 52.31% | -223.95% | -45.86% | -673.64% | -1,086.37% | -1,946,682.93% | 0.00% | -1,017.24% | -213.04% |
| Income Tax Expense | 325.00K | 488.00K | 319.00K | 284.00K | 263.00K | 229.00K | 3.89M | 175.00K | -3.67M | 195.00K | 218.00K | 242.00K | 964.00K | 689.00K | 228.00K | -1.35M | 2.14M | 0.00 | -22.41M | 7.19M | 53.84M | 0.00 | 100.00K | 4.10B | -2.30M | -1.10M | -1.20M |
| Net Income | -37.49M | -42.83M | -54.38M | -59.86M | -71.24M | -57.56M | -60.59M | -62.91M | -55.87M | -38.57M | -43.34M | -15.92M | -16.98M | -16.91M | -24.14M | -29.18M | -45.30M | -4.78M | 13.06M | -31.15M | -58.27M | -57.19M | -49.37M | -36.03M | -22.60M | -29.60M | -14.70M |
| Net Income Ratio | -23.98% | -26.43% | -41.55% | -65.12% | -95.44% | -94.51% | -139.06% | -169.18% | -163.25% | -105.65% | -109.28% | -43.38% | -51.39% | -73.18% | -134.22% | -176.78% | -410.21% | -13.43% | 53.60% | -223.95% | -602.87% | -673.64% | -1,088.58% | -1,946.68% | -941.67% | -1,020.69% | -213.04% |
| EPS | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.52 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.18 | 0.58 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| EPS Diluted | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.50 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.17 | 0.55 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| Weighted Avg Shares Out | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 130.83M | 108.19M | 101.46M | 96.07M | 74.77M | 67.57M | 54.52M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 26.87M | 22.35M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
| Weighted Avg Shares Out (Dil) | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 131.66M | 108.22M | 101.83M | 96.91M | 76.53M | 67.57M | 55.06M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 28.61M | 23.95M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2022. Recent developments and highlights include: First quarter 2022 total revenue of $43.0 million, reflecting a 46% increase over the prior year period....
Cerus Corporation Announces New Manufacturing and Supply Agreement With Fresenius Kabi For INTERCEPT Blood System Sets
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This new contract replaces the current one with Fresenius Kabi that was set to...
10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?
Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?
Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets. Under the terms of this contract, Cerus will continue to supply the Red...
Cerus Corporation to Release First Quarter 2022 Financial Results on May 5, 2022
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock market. The Company will host a conference call and webcast at...
Cerus Corporation to Participate at the Cowen 42nd Annual Health Care Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' chief financial officer, is scheduled to participate at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST. A live webcast...
Cerus Corporation (CERS) CEO Obi Greenman on Q4 2021 Results - Earnings Call Transcript
Cerus Corporation (CERS) CEO Obi Greenman on Q4 2021 Results - Earnings Call Transcript
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021. Recent developments and highlights include: Fourth quarter 2021 total revenue of $50.1 million, reflecting a 49% increase over the...
Cerus Corporation to Release Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market. The Company will host a conference call and...
Cerus Corporation: Outperforming And Gaining Momentum
Cerus Corporation: Outperforming And Gaining Momentum
Source: https://incomestatements.info
Category: Stock Reports